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A B S T R A C T
Mastoparan (MP) peptides, distributed in insect venoms, induce a local inflammatory response post envenoma-
tion. Most endogenous MPs share common structural elements within a tetradecapeptide sequence that adopts an
amphipathic helix whilst traversing biological membranes and when bound to an intracellular protein target. Ra-
tional modifications to increase cationic charge density and amphipathic helicity engineered mitoparan (MitP),
a mitochondriotoxic bioportide and potent secretagogue. Following intracellular translocation, MitP is accreted
by mitochondria thus indicating additional utility as an antimicrobial agent. Hence, the objectives of this study
were to compare the antimicrobial activities of a structurally diverse set of cationic cell penetrating peptides,
including both MP and MitP sequences, and to chemically engineer analogues of MitP for potential therapeutic
applications. Herein, we confirm that, like MP, MitP is a privileged structure for the development of antimicro-
bial peptides active against both prokaryotic and eukaryotic pathogens. Collectively, MitP and target-selective
chimeric analogues are broad spectrum antibiotics, with the Gram-negative A. baumannii demonstrating partic-
ular susceptibility. Modifications of MitP by amino acid substitution at position-14 produced peptides, Δ14MitP
analogues, with unique pharmacodynamic properties. One example, [Ser⁠14]MitP, lacks both cytotoxicity against
human cell lines and mast cell secretory activity yet retains selective activity against the encapsulated yeast C.
neoformans.
1. Introduction
Animal venoms usually comprise a complex mixture of peptide tox-
ins that act potently and rapidly when envenomated into soft tissues
[1]. Such venoms are, therefore, a remarkable resource for the discov-
ery of bioactive peptides highly active against every generic class of
protein drug target. Approximately 50% of the venom of the Korean
leather-jacket Vespula lewisii consists of the peptide mastoparan (MP;
INLKALAALAKKIL), named to signify its capacity to activate mast cell
secretion by a receptor-independent mechanism [2]. Moreover, as de-
scribed herein, MP is not a peptide species but rather a genus of struc-
turally related tetradecapeptides from hymenopteran venoms which in-
duce receptor-independent mast cell degranulation to promote pain and
other local inflammatory responses [3].
The term privileged scaffold was introduced by Evans et al. [4] to
serve as a general descriptor of a molecular framework or architecture
that can be readily modified to produce ligands for distinct receptors.
This original study focussed upon the advantages of the benzodiazepine
nucleus that seemingly resulted from the molecular mimicry of a beta
turn. However, since this time a variety of other privileged structures
and scaffolds have been identified and exploited [5] of which examples
pertinent to this study include peptides, peptoids, cyclic peptides and
a variety of conformation-constrained structural mimetics [6,7]. There
are several structural motifs almost invariably maintained by all en-
dogenous MPs. Ile always occupies the amino terminus of endogenous
peptides. Enzymatic cleavage of Ile⁠1 by enzymes in human serum is
relatively slow, but the resulting tridecapeptide, NLKALAALAKKIL, has
much reduced activity against Gram-negative Acinetobacter baumannii
compared with MP [8]. The MP tetradecapeptides are cationic in na-
ture, positive charges being contributed mostly by the ε-amino function
of multiple Lys residues. Leucinamide usually occupies the carboxyl-ter-
minal of endogenous MP analogues and loss of the amide function is
detrimental to biological activities including erythrocyte lysis and mast
cell degranulation [9,10]. The formation of an amphipathic alpha helix
is also a major determinant of the many activities of MP peptides. The
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structure of MP is disordered in aqueous solution but becomes helical in
the presence of lipids and membrane mimetics [11,12]. MP is also heli-
cal when bound to a primary intracellular protein target, namely pertus-
sis toxin-sensitive heterotrimeric G proteins [13,14]. As reviewed else-
where [15,16], the privileged nature of MP peptides enables them to
influence the activities of many additional protein targets that include
Ca⁠2+-ATPases [17], calmodulin [18] and glycogen phosphorylase [19].
The capacity of MP peptides to translocate cell membranes as an
amphipathic helix facilitates the presentation of a cationic hydrophilic
face on the inner side of the plasma membrane. This in turn mimics
some structural determinants of activated G protein-coupled receptors
[3,20–22]. Hence, the design of mitoparan (MitP; [Lys⁠5,8, Aib⁠10]MP;
Aib=2-aminoisobutyric acid) was dictated by the strategy of substitut-
ing additional cationic charge into the hydrophilic face of MP [23]. The
substitution of Ala⁠10 with Aib, a known helix promoter [24,25], was
intended to both increase the propensity for helix formation and also
confer resistance to proteases. The design of MitP deliberately included
Ile⁠1 and leucinamide⁠14 to maintain some structural determinants of the
privileged scaffold of MP. When directly compared with MP [23], MitP
is a more potent secretagogue of ß-hexosaminidase, a secretory gran-
ule marker, from RBL-2H3 mast cells and displays enhanced cytotoxic-
ity when exogenously added to U373MG astrocytoma cells. Of specific
relevance to this study, MitP and chimeric analogues, N-terminally ex-
tended with additional homing motifs, are specifically accreted by mito-
chondria following their efficient cellular translocation into eukaryotic
cells [26,27]. Moreover, MitP promotes apoptosis through mechanisms
that include the increased phosphorylation of mitogen-activated protein
kinases and the release of cytochrome c from mitochondria [23,26]. The
latter response is mediated, at least in part, by the modulation of volt-
age-dependent ion channels (VDAC) expressed in mitochondrial mem-
branes [26].
As further described herein, endogenous MP analogues are reported
to display a wide range of antibiotic activities. Thus, we reasoned that
MitP, a peptide that specifically accretes within mitochondria, could be
further engineered as an antibacterial agent. Accepting the endosymbi-
otic origin of the eukaryotic mitochondrion [28], we considered it likely
that MitP analogues could also interact with both the lipid and pro-
tein constituents of prokaryotic cell membranes. However, it is obvious
that the clinical utility of any antibiotic peptide that simultaneously pro-
motes mast cell degranulation and/or eukaryotic cell death would be se-
verely compromised. Thus, the major objective of this study was to iden-
tify MitP analogues with more desirable and selective antibiotic proper-
ties. When modelled as a classic α-helix, the highly conserved aliphatic
side chain of leucinamide⁠14 clearly contributes to the hydrophobic face
of endogenous MP sequences. Our approach to this problem was to sub-
tly perturb the privileged structure of MitP through the selective modifi-
cation of the carboxyl terminal. Our findings provide powerful evidence
that minor changes to the privileged structure of MitP can indeed be
employed to engineer selective antibacterial and antifungal agents.
2. Materials and methods
2.1. Materials
Fluorenylmethyloxycarbonyl (Fmoc)-protected amino acids for mi-
crowave-assisted peptide synthesis were purchased from Novabiochem
(Beeston, UK). AGTC Bioproducts Ltd (Hessle, UK) supplied dimethyl-
formamide, dichloromethane and piperidine for solid phase peptide syn-
thesis. Mammalian culture medium and supplements were purchased
from Sigma-Aldrich (Poole, K). Microbial assay plates were purchased
from Corning (Australia). Bacterial growth medium was purchased from
Bacto Laboratories (Mount Ptitchard, NSW, Australia) and
fungal growth medium and culture agar from Becton Dickinson (North
Ryde, NSW, Australia). Unless otherwise indicated all other research
grade chemicals were purchased from Sigma-Aldrich (Poole, UK or Cas-
tle Hill, NSW, Australia).
2.2. Microwave-assisted solid phase peptide synthesis
Solid phase peptide syntheses were performed using a Discover SPS
Microwave Peptide Synthsizer (CEM Microwave Technology Ltd, Buck-
ingham, UK) with fibre optic temperature control [29]. Peptides were
synthesized (0.1mmol scale) using Rink amide MBHA resins pre-loaded
with the first amino acid (AnaSpec, Inc. Cambridge Bioscience Ltd,
Cambridge, UK) and employed an N-α-Fmoc protection strategy with
O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexaflu-
orophosphate (HCTU; AGTC Bioporoducts) activation. Deprotection
with 7ml of 20% piperidine was performed for 3min at 50W/75°C.
A majority of AA coupling reactions were accomplished with a 4-fold
molar excess of Fmoc-protected AA with HCTU and diisopropylethy-
lamine (DIPEA), molar ratio of 1:1:2 (AA/HCTU/DIPEA), in 4ml for
10min at 25W/75°C. Arg coupling was performed in two stages: 30min
0W/∼25°C followed by 5min at 17W/75°C. To reduce racemization of
Cys and His, coupling conditions were 5min at 0W/∼25°C followed by
6min at 17W/50°C with the hindered base collidine (TMP) at molar ra-
tio of 1:1:2 (AA/HCTU/TMP) [30]. Aspartimide formation was reduced
by the substitution of piperidine with 5% piperazine and 0.1M 1-hy-
droxybenztriazole hydrate (HOBt) in the deprotection solution [30].
Fluorescent peptides to be used in confocal live cell imaging were
synthesised by amino-terminal acylation with the single isomer 6-car-
boxy-tetramethylrhodamine (TAMRA; Novabiochem, Beeston, UK).
All peptides were purified to apparent homogeneity by semi-prepar-
ative scale high performance liquid chromatography and lyophilised. As
reported herein (Table 2), the predicted masses of novel MitP analogues
described in this study (average M+H⁠+) were confirmed by matrix-as-
sisted laser desorption ionization (MALDI) time of flight mass spectrom-
etry operated in positive ion mode [26].
2.3. Mammalian cell culture
Rat basophilic leukaemia cells (RBL-2H3) are widely employed as
an accepted mucosal mast cell model for the investigation of regulated
secretory phenomenon and were therefore used to evaluate the secre-
tory effects of MitP analogues [29,31,32]. RBL-2H3 were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) containing l-glutamine
(0.1mg/ml) supplemented with foetal bovine serum 10% (v/v), peni-
cillin (100U/ml) and streptomycin (100μg/ml) in a humidified atmos-
phere of 5% CO⁠2 at 37°C.
U373MG human astrocytoma cells are an extensively-characterised
and routinely-used cellular model within our laboratory for the in-
vestigation of peptide-induced cytotoxic events [26,31,33] and were
therefore used to determine the cytotoxicity profiles of MitP analogues.
HEK293 cells were additionally utilised for cytotoxic screening. Both
U373MG and HEK293 were maintained in DMEM as above.
2.4. Secretory efficacies of MP and MitP analogues
To determine the secretory efficacies of polybasic peptides, the ex-
ocytosis of β-hexosaminidase, a secretory lysosomal marker, was de-
termined in RBL-2H3 cells as previously described [29,34–36]. ß-Hex-
osaminidase was assayed in samples of cell medium following exoge-
nous application of peptides to RBL-2H3 cells in HAMS F12 medium.
5μl Aliquots of medium were transferred into 96 well plates and in-
cubated with ρ-nitrophenyl-N-acetyl-ß-d-glucosamide (20μl of 1mM in
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0.1M sodium citrate buffer, pH 4.5) for 1h at 37°C. Na⁠2CO⁠3/NaHCO⁠3
buffer (200μl of 0.1M, pH 10.5) was then added and ß-hexosaminidase
activity determined by colourimetric analysis at 405nm.
2.5. Eukaryotic cytotoxicity assays
Peptide-induced changes in cellular viability were quantitatively as-
sessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) conversion assay [26,37]. U373MG cells were cultured
as above in 96 well plates, treated with peptides for 4h at 37°C, and
further incubated with MTT (0.5g/L) for 3h at 37°C. The insoluble for-
mazan product was solubilised with DMSO and MTT conversion de-
termined by colorimetric analysis at 540nm. Cellular viability was ex-
pressed as a percentage of those cells treated with vehicle (medium)
alone. Graphical representations of changes in cell viability were calcu-
lated using GraphPad Prism 7 software.
Peptide-induced changes in eukaryotic cell viability were also per-
formed by the CO-ADD (Community for Antimicrobial Drug Discovery)
and used HEK293 cells. Cells were counted manually in a Neubauer
haemocytometer and then plated in 384-well plates containing peptides
to give a density of 6000 cells/well in a final volume of 50μL and in-
cubated for 20h at 37°C in 5% CO⁠2. Cytotoxicity was measured by flu-
orescence, Ex: 560/10nm, Em: 590/10nm (F⁠560/590), after addition of
5μL of 25mg/L Resazurin (2.3mg/L final concentration) and after incu-
bation for a further 3h at 37°C in 5% CO⁠2. The fluorescence intensity
was measured using a Tecan M1000 Pro monochromator plate reader,
using the automatic gain calculation. CC⁠50 (concentration at 50% cyto-
toxicity) values were calculated by curve fitting the inhibition values
vs. log (concentration) and used the sigmoidal dose-response function,
with variable fitting values for bottom, top and slope. The curve fitting
was implemented using Pipeline Pilot's dose-response component (giv-
ing similar results to comparative software such as GraphPad's Prism
and IDBS's XlFit).
2.6. Live cell confocal imaging
U373MG cells were transferred to 35mm Petri Dishes with 12mm
glass bases (PAA) and grown to 90% confluence (conditions as de-
scribed above). Prior to the addition of 5μM TAMRA-labelled peptides
and 200nM Mitotracker⁠® Green FM (Molecular Probes, Invitrogen, Pais-
ley, UK), cells were washed with and transferred into phenol red-free
DMEM. During the period of exposure to peptides, cell layers were
maintained at 37°C in a humidified atmosphere of 5% CO⁠2. Immedi-
ately prior to observation, cells were washed gently (8×) and analysed
with a Carl Zeiss LSM 880 confocal microscope equipped with a live cell
imaging chamber [26,27].
2.7. Identification and characterisation of antimicrobial peptides
All antimicrobial assays detailed below were performed by CO-ADD
funded by the Wellcome Trust (UK) and The University of Queensland
(Australia).
2.7.1. Primary antimicrobial screening
To select cationic membrane translocating peptides for further analy-
ses, whole cell growth inhibition assays were performed at a single con-
centration of 32mg/L, in duplicate (n=2). These assays included 5
bacterial pathogens: Escherichia coli, Klebsiella pneumoniae, Acinetobac-
ter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus, and 2
fungi: Candida albicans and Cryptococcus neoformans. Assays were per-
formed as below.
The significance of the inhibition values was determined by modi-
fied Z-scores, calculated using the median and MAD of the samples (no
controls) on the same plate. Samples with inhibition value above 80%
and Z-Score above 2.5 for either replicate (n=2 on different plates)
were deemed as active. Candidate active antimicrobial peptides were
further assayed to ascertain MIC values as described below.
2.7.2. Sample preparation
Peptides were prepared to a 10mg/mL stock in water and stored at
−20°C. Peptides were further prepared in water to 32mg/L and seri-
ally diluted 1:2 fold, 8 times. Each sample concentration was prepared
in 384-well plates, non-binding surface plate (Corning 3640) for each
bacterial/fungal strain and performed in triplicate (n=3). All the sam-
ple preparation was performed using liquid handling robots.
2.7.3. Antibacterial assays
All bacteria were cultured in Cation-adjusted Mueller Hinton broth
at 37°C overnight. A sample of each culture was then diluted 40-fold
in fresh broth and incubated at 37°C for 1.5–3h. The resultant mid-log
phase cultures were diluted (CFU/mL measured by OD⁠600), then added
to each well of the compound containing plates, giving a cell density of
5×10⁠5CFU/mL and a total volume of 50μL. All the plates were covered
and incubated at 37°C for 18h without shaking.
Inhibition of bacterial growth was determined measuring ab-
sorbance at 600nm (OD⁠600), using a Tecan M1000 Pro monochroma-
tor plate reader. The percentage of growth inhibition was calculated
for each well, using the negative control (medium only) and positive
control (bacteria without inhibitors) on the same plate as references.
The MIC was determined as the lowest concentration at which the
growth was fully inhibited, defined by an inhibition ≥80%. In addition,
the maximal percentage of growth inhibition is reported as DMax, in-
dicating any compounds with partial activity. Hits were classified by
MIC≤16mg/L.
2.7.4. Antifungal assays
Fungi strains were cultured for 3days on Yeast Extract-Peptone Dex-
trose agar at 30°C. A suspension of 1×10⁠6–5×10⁠6CFU/mL (as deter-
mined by OD⁠530) was prepared from five colonies. The suspension was
subsequently diluted and added to each well of the compound-contain-
ing plates giving a final cell density of fungi suspension of 2.5×10⁠3CFU/
mL and a total volume of 50μL. All plates were covered and incubated
at 35°C for 36h without shaking.
Growth inhibition of C. albicans was determined measuring ab-
sorbance at 530nm (OD⁠530), while the growth inhibition of C. neofor-
mans was determined measuring the difference in absorbance between
600 and 570nm (OD⁠600-570), after the addition of resazurin (0.001% fi-
nal concentration) and incubation at 35°C for an additional 2h period.
The absorbance was measured using a Biotek Synergy HTX plate reader.
In both cases, the percentage of growth inhibition was calculated for
each well, using the negative control (medium only) and positive con-
trol (fungi without inhibitors) on the same plate. The MIC was deter-
mined as the lowest concentration at which the growth was fully inhib-
ited, defined by an inhibition ≥80% for C. albicans and an inhibition
≥70% for C. neoformans. Due to a higher variance in growth and in-
hibition, a lower threshold was applied to the data for C. neoformans.
In addition, the maximal percentage of growth inhibition is reported as
DMax, indicating any compounds with marginal activity. Hits were clas-
sified by MIC≤16mg/L.
2.7.5. Antibiotic standards, preparation and quality control (QC)
Colistin and Vancomycin were used as positive bacterial inhibitor
standards for Gram-negative and Gram-positive bacteria, respectively.
Fluconazole was used as a positive fungal inhibitor standard for C. albi-
cans and C. neoformans. Tamoxifen was used as a positive cytotoxicity
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standard. Antibiotics were used at 4 concentrations, with 2 above and 2
below its MIC or CC⁠50 value.
The QC of the assays was determined by the Z’-Factor, calculated
from the negative (medium only) and positive controls (bacterial, fun-
gal or cell culture without inhibitor) and the standards. Plates with a
Z’-Factor of ≥0.4 and standards active at the highest and inactive at the
lowest concentration, were accepted for further data analyses.
2.8. Statistical analyses
All statistical analyses were performed using GraphPad Prism 7 soft-
ware. Results are expressed as mean±SEM, unless otherwise stated in
the designated figure legend. Comparisons of 3 or more groups of data
were performed using one-way ANOVA followed by Dunnett’s multi-
ple comparison test to compare experimental values to the identified
control. Comparisons of 2 sets of data used Student’s t-tests. P val-
ues were calculated using GraphPad Prism 7 and presented accord-
ingly: ****, extremely significant, p<0.0001; ***, extremely signifi-
cant, p=0.0001–0.001; **, very significant, p=0.001–0.01; *, signifi-
cant, p=0.01–0.05; p>0.05 were deemed statistically insignificant.
The presented investigation considers the following Null hypotheses
(H⁠0);
H⁠01: There is no significant growth inhibition of microbial cells
treated with MitP and related analogues compared to cells treated with
medium alone.
H⁠02: There is no significant difference in eukaryotic cellular cytotoxi-
city following treatment with position-14 modified MitP (Δ14MitP) ana-
logues compared to MitP alone.
H⁠03: There is no significant difference in mast cell secretory activity
following treatment with Δ14MitP analogues compared to MitP alone.
3. Results
Table 1 highlights the broad range of antibiotic activities of endoge-
nous MPs and structural homologues to date. However, if indeed de-
termined, these peptides clearly exhibit cytotoxicity towards eukaryotic
cells and demonstrate mast cell stimulatory properties.
3.1. Eukaryotic cytotoxicity profiles of Δ14MitP analogues
U373MG human astrocytoma cells were used to determine the cy-
totoxicity profiles of our newly synthesised position-14 modified MitP
(Δ14MitP) analogues (Table 2, Fig. 1). We have previously reported
that maximum reductions in U373MG cell viability are evident fol-
lowing 4h exposure to MitP and associated analogues [26,31]. Fig. 1
clearly demonstrates that the viability of cells treated with [Ser⁠14]MitP,
[Orn⁠8,Ser⁠14]MitP or [Thr⁠14]MitP exceeded 80% even following 4h treat-
ment at a final peptide concentration of 30μM. Moreover, at a pep-
tide concentration of 30μM, all Δ14MitP analogues demonstrated a re-
duction in cytotoxicity compared to MitP at the same concentration
(p<0.0001, Fig. 1).
The rationale for substitution of Leu with Trp at position-14 of MitP
was to minimise eukaryotic cell toxicity [38,39]. However, and despite
a statistically significant reduction in U373MG cytotoxicity when com-
pared to MitP, 30μM [Trp⁠14]MitP reduced cell viability to 44.3% when
compared to untreated (medium alone) cells (p<0.0001, paired t-test,
Table 1
Primary sequences of MP-related peptides and selected biological activities. Unless otherwise indicated, all peptides have an amidated carboxyl terminal. Note that Leu occupies posi-
tion-14 in a majority of endogenous sequences. In many cases peptides with antibacterial activities have not been tested in eukaryotic cell systems. D-amino acids are shown in lower case.
*Indicates an activity that is greatly attenuated compared with other MP analogues. Abbreviations: Adec, 2-amino-decanoamide; Gu, guanidinyl; MC, mast cell; ND, not determined.
Sequence Cytotoxicty MC secretion References
Prokaryote Eukaryote
Endogenous peptides
Mastoparan (MP) INLKALAALAKKIL Gram +, Gram − Yes Yes [50]
MP-AF INLKAIAALAKKLF Gram − ND ND [70]
EMP-AF INLLKIAKGIIKSL Gram +, Gram − ND Yes [50,72]
MP-B LKLKSIVSWAKKVL Gram +, Gram − ND ND [53]
HR1 INLKALAALVKKVL Gram + ND Yes [50]
MP-VB1 INMKASAAVAKKLL Gram +, Gram − Yes Yes [51]
MP-X INWKGIAAMAKKLL Gram +, Gram − Yes Yes [57,73]
MP-S LRLKSIVSYAKKVL Gram +, Gram − Yes ND [74]
Polybia-MP-II INWLKLGKMVIDAL Gram +, Gram − Yes Yes [51]
PDD-A INWKKIFEKVKNLV Gram +, Gram − ND Yes [75]
Structural homologues
MK4589 INWKKIAKKVAGML Gram +, Gram − ND Yes* [10]
Gu-MP Gu-INLKALAALAKKIL Gram − ND ND [8]
Inverso-MP inlkalaalakkil Gram +, Gram − Yes Yes [8,10]
MP-CH⁠2CH⁠2NH⁠2 INLKALAALAKKIL-CH ⁠2CH⁠2NH⁠2 Gram − ND ND [10]
[Ala⁠14]MP-X INWKGIAAMAKKLA Gram +, Gram − ND ND [57]
[Adec⁠14]MP-X INWKGIAAMAKKL(Adec) Gram +, Gram − ND ND [57]
Table 2
The primary sequences and confirmed masses of candidate antimicrobial peptides. All peptides are amidated at the carboxyl terminal. The substitution of Lys with Orn in [Orn⁠8, Ser⁠14]MitP
was intended to confer proteolytic resistance whilst maintaining cationic charge density. D-amino acids are written in lower case.
Peptide Sequence Predicted mW Confirmed mW
[Ser⁠14]MitP H-INLKKLAKL(Aib)KKIS-NH⁠2 1581.1 1581.0
[Orn⁠8, Ser⁠14]MitP. H-INLKKLA(Orn)L(Aib)KKIS-NH⁠2 1567.1 1567.1
[Thr⁠14]MitP H-INLKKLAKL(Aib)KKIT-NH⁠2 1595.1 1595.0
MitP H-INLKKLAKL(Aib)KKIL-NH⁠2 1607.1 1607.1
Z-Gly-RGD ⁠DPhe-MitP Z-GRGDf INLKKLAKL(Aib)KKIL-NH⁠2 2273.8 2273.5
Z-Gly-RGE ⁠DPhe-MitP Z-GRGEf INLKKLAKL(Aib)KKIL-NH⁠2 2287.9 2287.7
Abbreviations: Aib, 2-aminoisobutyric acid; Orn, ornithine; Z, carboxybenzyl.
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Fig. 1. Comparative eukaryotic cell cytotoxicity profiles of Δ14MitP analogues. Δ14MitP
analogues demonstrated reduced cytotoxicity of U373MG cells compared to MitP. Cells
were treated with Δ14MitP analogues for 4h at the concentrations indicated: [Ser⁠14]MitP
(filled square), [Orn⁠8,Ser⁠14]MitP (filled circle), [Thr⁠14]MitP (filled triangle), [Trp⁠14]MitP
(open triangle) and MitP (open circle). Cell viability was measured by MTT conversion
and expressed as a percentage of those cells treated with vehicle (medium) alone. Data
points are mean±SEM from 3 experiments performed in quadruplicate. Statistical analy-
sis: Data were analysed using one-way ANOVA. Post hoc analysis used Dunnett’s multiple
comparison test to compare viability changes to MitP (positive control) at the correspond-
ing peptide concentrations, (****p<0.0001, **p<0.001, *p<0.05).
one-tailed) and was therefore deemed to demonstrate cytotoxic effects
within eukaryotic cells. MitP was used in this experiment as a positive
control and, in accordance with previous findings [26,31] reduced cell
viability to 4.1%.
As an additional assessment of potential cytotoxic effects in eukary-
otic cells, HEK293 cells were treated with increasing concentrations of
([Ser⁠14]MitP), [Orn⁠8,Ser⁠14]MitP and [Thr⁠14]MitP for 3h. As with cyto-
toxicity data using U373MG cells, these peptides were deemed to be
inactive giving CC⁠50 values of >32mg/L and gave maximal responses
(DMax) which demonstrated a reduction in cytotoxicity compared to
MitP (p<0.0001, Table 3). In contrast, MitP and target-selective ana-
logues [26], Z-Gly-RGD⁠DPhe-MitP and Z-Gly-RGE⁠DPhe-MitP, were con-
firmed to be cytotoxic in this system giving CC⁠50 values of ≤32μg/mL
(Table 3).
Table 3
Cytotoxicity profiles of candidate cationic CPP using HEK293 cells. CC⁠50 values were de-
termined at the concentration (mg/L) at which 50% cytotoxicity occurred in HEK293 cells.
CC⁠50 values with>indicate samples with no activity (low DMax value). Cytotoxicity was
classified by CC⁠50 ≤32μg/mL. DMax indicates maximal response at the highest concentra-
tion tested (32mg/L). Data are expressed as ranges from 2 independent experiments. Data
were analysed using one-way ANOVA. Post hoc analysis used Dunnett’s multiple compar-
ison test to compare DMax values to those of MitP, (****P<0.0001).
Peptide HEK293 Cytotoxicity
CC⁠50 (mg/L) DMax
[Ser⁠14]MitP >32 [14.5, 15.5]****
[Orn⁠8,Ser⁠14]MitP >32 [16.4, 18.7]****
[Thr⁠14]MitP >32 [18.3, 19.4]****
MitP [19.1, 20.6] [85.4, 86.5]
Z-Gly-RGD ⁠DPhe-MitP [16.7, 19.7] [96.9, 99.9]
Z-Gly-RGE ⁠DPhe-MitP [15.3, >32.0] [97.4, 99.7]
LRRK2⁠2413–2427 >32 [16.0, 19.7]****
3.2. Diminished mast cell secretory properties of Δ14MitP analogues
RBL-2H3 cells were used as a mucosal mast cell model and secre-
tory events were determined by assaying the exocytosis of the lysoso-
mal marker β-hexosaminidase. We have previously reported [23] that
MitP demonstrates an enhanced secretory efficacy compared to MP. Se-
cretory efficacy indices presented here indicate the above basal activi-
ties of peptide analogues as a fraction of that of MP and are determined
at a concentration of 30μM. Accordingly, MitP gave a secretory effi-
cacy index of 2.83 and Δ14MitP analogues gave, in descending order,
efficacy indices of 1.13 ([Trp⁠14]MitP), 0.79 ([Thr⁠14]MitP), 0.60 ([Orn⁠8,
Ser⁠14]MitP) and 0.29 ([Ser⁠14]MitP). Fig. 2 shows the concentration-de-
pendent exocytosis of β-hexosaminidase in response to MitP analogues
and further highlights the complete absence of mast cell degranulation
in response to treatment with [Ser⁠14]MitP, even at a final assay concen-
tration of 30μM. Moreover, when comparing secretory efficacies (fold/
basal) at peptide concentrations of 10μM and 30μM, all Δ14MitP ana-
logues demonstrated a significant decrease (p<0.0001) in secretory re-
sponse compared to MitP at these corresponding concentrations, (Fig.
2).
3.3. Cellular penetration and mitochondrial accretion of Δ14MitP
analogues
Considering the probable endosymbiotic origin of mitochondria [28]
and the fact that MitP translocates eukaryotic plasma membranes to
subsequently and specifically redistribute to mitochondria [26],
Δ14MitP analogues were assessed for their mitochondrial co-localiza
Fig. 2. Comparative secretory activities of Δ14MitP analogues. Δ14MitP analogues
demonstrated reduced secretory efficacies compared to MitP. RBL-2H3 cells were treated
with peptides at the concentrations indicated and medium assayed for the secretory
marker β-hexosaminidase: [Ser⁠14]MitP (filled square), [Orn⁠8,Ser⁠14]MitP (filled circle),
[Thr⁠14]MitP (filled triangle), [Trp⁠14]MitP (open triangle), MP (open square) and MitP
(open circle). Data are expressed as fold over basal (medium alone) levels of β-hex-
osaminidase secretion and data points are mean±SEM from 3 experiments performed in
quadruplicate. Data were analysed using one-way ANOVA. Post hoc analysis used Dun-
nett’s multiple comparison test to compare secretory efficacies (fold/basal) to that of MitP
(positive control) at the corresponding peptide concentration, (****p<0.0001).
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tion propensity. Fig. 3 indicates that 5μM TAMRA-labelled [Ser⁠14]MitP,
[Orn⁠8, Ser⁠14]MitP and [Thr⁠14]MitP strongly co-localize with mitochon-
dria in U373MG cells. It is noteworthy that, despite a lack of measured
U373MG cellular cytotoxicity, mitochondria demonstrate a condensed
morphology following treatment with these analogues (Fig. 3a–c).
Moreover, mitochondrial morphology remained unaltered within
U373MG cells following treatment with TAMRA-[Trp⁠14]MitP (5μM).
This observation was accompanied by a distinct absence of mitochondr-
ial co-localization. Paradoxically and as stated previously, [Trp⁠14]MitP
was the most cytotoxic of all Δ14MitP analogues reducing cell via-
bility to 44.3% (p<0.0001) at a maximal peptide concentration of
30μM (Fig. 1). These data indicate that [Trp⁠14]MitP-induced cytotox-
icity of eukaryotic cells is a likely consequence of random membrane
perturbation and not a specific mitochondriotoxic phenomena as
Fig. 3. Live confocal cell imaging analysis of the intracellular distributions of Δ14MitP analogues. U373MG cells were treated with 5μM TAMRA-labelled MitP analogues and Mito-
tracker⁠® Green FM (200nM) for 1h and viewed with an LSM 880 microscope equipped with a live cell imaging chamber. Scale bars are 20μm. [Ser⁠14]MitP (a), [Orn⁠8, Ser⁠14]MitP (b) and
[Thr⁠14]MitP (c) demonstrated both U373MG cellular penetration and mitochondrial co-localization (depicted by yellow co-localization, merged panels). [Trp⁠14]MitP (d), despite being cell
penetrant, did not co-localize with mitochondria. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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reported for other MitP analogues [26]. Due to its propensity to induce
eukaryotic cell death and promote mast cell degranulation comparable
to that of MP (Fig. 2), [Trp⁠14]MitP was excluded from any further an-
timicrobial screening.
3.4. Primary antimicrobial screening and identification of candidate
antimicrobials
Initial screening of a broad range of polycationic cell penetrat-
ing peptides (CPPs) was performed at a single peptide concentration
of 32mg/L (n=2) and measured inhibition of growth against 5 bac-
teria; Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumanni,
Pseudomonas aeruginosa and Staphylococcus aureus and 2 fungi: Can-
dida albicans and Cryptococcus neoformans. The peptides highlighted in
Table 2 were deemed active according to the following criteria; in-
hibition of bacterial or fungal growth was ≥80% and a Z-score≥2.5.
The target-specific MitP analogues Z-Gly-RGD⁠DPhe-MitP and
Z-Gly-RGE⁠DPhe-MitP were also included in this study owing to the en-
hanced propensity of Z-Gly-RGD⁠DPhe-MitP to accrete at mitochondrial
membranes [27]. Primary antimicrobial screening further highlighted
the antimicrobial potential of the privileged structure that is MP. Ac-
cordingly, 6 of the 7 candidate antimicrobials were MP analogues,
whereas the remaining 13 polycationic CPP were deemed to be inactive
against all organisms included in this study. Inactivity was based on in-
hibition of bacterial or fungal growth <80% or a Z-score of <2.5 and
was reported for the following polycationic peptides: Sequences derived
from human cytochrome c (Cyt c⁠[33]), Cyt c ⁠4−13 (H-EKGKKIFIMK-NH⁠2),
Cyt c⁠5−13 (H-KGKKIFIMK-NH⁠2), Cyt c⁠79−88 (H-KMIFVGIKKK-NH⁠2); a se-
quence derived from Na⁠+K⁠+ATPaseγ (H-LSRRFR(Aib)GGNKKR-
RQIN-NH⁠2); Sequences derived from the leucine rich repeat kinase 2
(LRRK2⁠[27]), LRRK2⁠1322−1340 (H-LQQRLKKAVPYNRMKLMIV-NH⁠2), LR-
RK2⁠1546−1564 (H-PVIDRKRLLQLVRENQLQL-NH⁠2), LRRK2⁠754−755 (H-SP-
KLVELLLNSGSREQDVRKAL-NH⁠2), LRRK2⁠754−775 (P755L) (H-SLKLVEL-
LLNSGSREQD
VRKAL-NH⁠2), [DArg⁠1, Aib⁠12]LRRK2⁠2413−2427 (H-rVKTL-
CLQKNT(Aib)LWI-NH⁠2), LRRK2⁠1116−1136 (H-GNKISGICSPLR-
LKELKILNL-NH⁠2), LRRK2⁠1367−1386 (H-ATVGIDVKDWPIQIRD-
KRKR-NH⁠2), LRRK2⁠1367−1386 (I1371V)Mut (H-ATVGVDVKDWPIQIRD-
KRKR-NH⁠2), and a sequence derived from the eye-specific ovo transcrip-
tion factor of the planarian Schmidtea mediterranea (H-IVKTIKVKRRN-
FAEYIKKL-NH⁠2).
3.5. MIC and DMax values of candidate antibacterial agents
MICs were determined as the lowest concentration at which growth
was fully inhibited and defined by an inhibition ≥80%, (Table 4).
MitP, according to the criteria stipulated in Table 4 (MIC≤16mg/L)
demonstrated activity against all 5 bacteria, Z-Gly-RGD⁠DPhe-MitP was
active against 4 and Z-Gly-RGE⁠DPhe-MitP was active against 3. How-
ever, Δ14MitP analogues, with proven diminished propensities to pro-
mote mast cell secretion (Fig. 2) and induce death of eukaryotic cells
(Fig. 1), gave high MIC values (≥32mg/L, the highest concentration
tested), (Table 4). Nonetheless, Δ14MitP analogues inhibited the growth
of A. baumannii by maximum mean values of 86.27% ([Thr⁠14]MitP),
71.34% ([Ser⁠14]MitP) and 65.67% ([Orn⁠8, Ser⁠14]MitP) when compared
to control cells treated with medium alone, (P<0.0001, ANOVA and
post hoc Dunnett’s comparison, Table 4). It is thus tempting to spec-
ulate that other amino acid substitution at position-14 of MitP might
produce more potent antibiotics against this Gram-negative bacterium.
Additionally, and using the same statistical analysis as above, [Orn⁠8,
Ser⁠14]MitP exhibited a mean maximal inhibitory growth response of
76.57% against P. aeruginosa (p<0.0001, Table 4).
3.6. MIC values of candidate antifungal agents
MICs were determined as the lowest concentration at which growth
was fully inhibited and defined by an inhibition ≥80% for C. albicans
Table 4
MICs (mg/L) and DMax values for candidate antimicrobial cationic CPPs.
Antibacterial: The MIC (mg/L) was determined as the lowest concentration at which the growth was fully inhibited, defined by an inhibition ≥80%. In addition, the maximal percentage
of growth inhibition is reported as DMax (maximal response), which additionally indicates any compounds with partial activity at the maximum screened concentration (32mg/L).
Antifungal: The MIC was determined as the lowest concentration at which the growth was fully inhibited, defined by an inhibition ≥80% for C. albicans and an inhibition ≥70% for C.
neoformans. In addition, the maximal percentage of growth inhibition is reported as DMax, indicating any compounds with marginal activity.
Hits were classified by MIC≤16mg/L and shaded in grey. MIC values with >indicate samples with a low DMax value (<80%) and partial activity at the highest concentration tested. A
majority of data are expressed as mean±S.E.M (n=3). DMax values for [Ser⁠14]MitP, [Orn⁠8, Ser⁠14]MitP and [Thr⁠14]MitP are mean±S.E.M (n=5). Dmax values for classified hits underwent
further statistical analysis to establish significant growth inhibition when compared to cells treated with medium alone, (****P<0.0001, ***P<0.001, one-way ANOVA followed by
Dunnett’s multiple comparison test).
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and an inhibition ≥70% for C. neoformans. Table 4 highlights that all
Δ14MitP analogues were deemed active against C. neoformans, giv-
ing MIC (mg/L) values of 3.67, 4.00 and 5.33 for [Thr⁠14]MitP, [Orn⁠8,
Ser⁠14]MitP and [Ser⁠14]MitP, respectively.
MitP, Z-Gly-RGD⁠DPhe-MitP and Z-Gly-RGE⁠DPhe-MitP demonstrated
activity against both C. neoformans and C. albicans, whilst LR-
RK2⁠2413−2427 was active against C. neoformans (Table 4). This latter pep-
tide was also confirmed to be non-cytotoxic in HEK293 cells (Table 3).
4. Discussion
Examples of endogenous peptide antibiotics are currently numbered
in their thousands [40–42]. Considering the pressing need to iden-
tify entirely new classes of antibiotic, particularly agents active against
Gram-negative organisms [43], peptides extracted from natural sources,
including those isolated from animal venoms [44,45], are a valuable
commodity. As described herein (Table 1), wasp venoms from many
species contain significant amounts of a MP peptide that, following en-
venomation, rapidly induces dolor, rubor, calor and tumor; four clas-
sic symptoms of acute inflammation. The common privileged structure
of MP peptides, mirrored in part by the mitochondriotoxic MitP, en-
ables this genus of peptides to cross biological membranes and regulate
the activities of protein targets that include heterotrimeric G proteins
[3,14–6]. This localized receptor-independent activation of MC secre-
tion, the primary response driving adverse reactions to wasp stings, is
a major caveat to the therapeutic utility of most MP-related cationic se-
quences Thus, a major objective of this study was to introduce minor
changes to the scaffold structure of MitP in order to maintain membrane
translocating activity but to reduce or negate both MC secretion and eu-
karyotic cell toxicity.
Of particular relevance to this study, many MP peptides have an-
timicrobial activities (Table 1) and there are other pertinent examples
of cationic α-helical peptide antibiotics which include the magainins
and cercopins [42]. As noted by others [46], the ability to cross or
intercalate into a biological membrane is a common feature of both
cationic cell penetrating peptides (CPPs) and many antibiotic peptides.
Moreover, we would classify antibiotic MP analogues as bioportides,
a designated class of bioactive CPPs distinct from inert delivery vec-
tors [47,48]. As described and presented herein (Table 4), MitP is a
broad-spectrum antimicrobial and could have utility for non-medical ap-
plications such as aquaculture and domestic usage. Moreover, the ex-
tensive structure activity relationships of endogenous and synthetic MP
analogues indicated that it could be possible to engineer novel ana-
logues of MitP devoid of undesirable biological activities. For example,
the synthetic MP analogue [Lys⁠10, Leu⁠13]MP (mas 11) lacks the usual
lytic activity of MP peptides but is a more potent activator of secretion
from rodent peritoneal MCs [49]. Hence, we chose to modify the car-
boxyl terminal of MitP, usually occupied by the hydrophobic residue
leucine, with other natural amino acids. For example, the substitution of
serine into position-14 directs a polar hydroxyl group at the distal end
of the hydrophobic face of [Ser⁠14]MitP when modelled as a 3.6⁠13 α-he-
lix, (Fig. 4).
A common biological activity of MP peptides is the ability to pro-
mote cell lysis or, more specifically, haemolysis [41,42,50–53]. This dis-
ruption of biological membranes by cationic peptides has been widely
proposed as a general mechanism of antibiotic activity. Both MP and
HR1 (Table 1) may accumulate on the outer surface of biological mem-
branes and promote membrane breakdown by the carpet mechanism
[50,54]. Accordingly, electrostatic interactions between α-helical
cationic peptides and negatively charged membrane components pro-
mote peptide accumulation at the membrane surface [55,56]. At a
critical concentration sufficient peptide, bound in an orientation
that is parallel to the membrane surface, “carpets” the bilayer to pro-
mote membrane disintegration by a detergent-like mechanism. Clearly,
the additional Lys residues added to the privileged scaffold of MitP ana-
logues (Fig. 4) would favour a molecular interaction with more an-
ionic bacterial membranes compared with more zwitterionic eukary-
otic plasma membranes [50,52]. However, a variety of alternative mem-
brane permeation mechanisms are possible [41,42,55,56] that may also
contribute to the molecular basis of membrane selectivity and antimi-
crobial activity observed amongst some MP peptides [50,55,57]. We
anticipate that future studies will more clearly define the antimicro-
bial mechanism of action of MitP analogues and such data will provide
guidelines for the engineering of second generation Δ14MitP analogues.
The privileged structure of MP and related sequences is readily mod-
ified either during or post synthesis and single amino acid substitutions
within a tetradecapeptide helix can produce dramatic changes in biolog-
ical activities [52–54] and/or membrane selectivity (Fig. 4). Of particu-
lar relevance to this study, the substitution of Ala at position-14 in MP-X
([Ala⁠14]MP-X; Table 1) resulted in a higher specificity for red blood cell
membranes compared with bacteria [57]. Similar substitution with the
more hydrophobic amino acid 2-amino-decanoic acid ([Adec⁠14]MP-X;
Table 1) increased bactericidal potency but reduced membrane selec-
tivity [57]. As exemplified by the collective biological activities of
Δ14MitP analogues, perturbation of the tertradecapeptide amphipathic
helical structure can diminish some undesirable properties of the par-
ent compounds whilst maintaining promising antimicrobial activities.
For example, [Ser⁠14]MitP entirely lacks the capacity of MitP and tar-
get-selective analogues to promote MC degranulation and is essentially
non-toxic when applied to eukaryotic cells, (Figs. 1 and 2, Table 3). Our
studies also confirmed (Fig. 3d) that [Ser⁠14]MitP is an efficient CPP and,
in common with MitP and some other analogues, accumulates within
mitochondria following efficient cellular entry. Significantly, the mito-
chondrial accretion of [Ser⁠14]MitP does not induce cell death by intrin-
sic apoptosis or other mechanisms. Considering the ubiquitous contri-
bution of mitochondrial membrane permeabilisation in the end stages
of eukaryotic cell death [58], this observation clearly indicates that the
substitution of a polar residue at position-14 in [Ser⁠14]MitP does not
prevent mitochondrial membrane accumulation but negates the activa-
tion of the voltage-dependent anion channel (VDAC) which leads to the
release of apoptogenic cytochrome c from mitochondria [26]. This ob-
servation also alludes to the possibility of using MitP analogues to target
intracellular microorganisms without detriment to the host cell. In con-
trast, [Trp⁠14]MitP displays significant cytotoxicty in eukaryotic cell sys-
tems (Fig. 1) and it was therefore initially predicted that [Trp⁠14]MitP,
as is the case with MitP, was inducing late intrinsic apoptotic events
through cooperation with the permeability transition pore-associated
protein VDAC, with a consequential release of cytochrome c and acti-
vation of the caspase cascade [26]. However, live confocal cell imag-
ing analysis (Fig. 3D) clearly demonstrates that [Trp⁠14]MitP does not ac-
crete within mitochondrial membranes and therefore suggests, particu-
larly within a 4h incubation period, a necrotic mechanism of cell death,
such as induction of non-specific perturbations of the plasma membrane
as is the case with high concentrations (>20μM) of many MP analogues
[10,23,31,50].
If general membrane perturbation is a common mechanism of ac-
tion of antimicrobial MitP analogues, then structural or biochemical dif-
ferences between mitochondrial, bacterial and fungal membranes might
provide some explanation for the distinct activity profiles of peptides
characterised and described herein. There is superficial ultrastructural
similarity between the double membrane systems of the eukaryotic mi-
tochondrion and Gram-negative bacteria including A. baumannii. Mi-
tochondrial membranes are composed of all of the major classes of
phospholipids that constitute eukaryotic plasma membranes, with the
addition of small quantities of cardiolipin [59]. Moreover, the mito
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Fig. 4. The tetradecapeptide helices of MP and MitP are privileged structures for drug discovery. The amphipathic natures of both MP and MitP can be observed when presented as helical
wheels with cationic charges illustrated in blue. MP has been successfully utilised in the development of chimeric CPPs of which transportan 10 (TP10) [76] has been widely studied.
The all D-amino acid inverso MP (iMP) [31] is also a highly efficient CPP. The selective targeting of the mitochondriotoxic MitP to tumour cells, perhaps as a component of a polymeric
delivery system [69], is a potential cancer therapy. As exemplified by the properties of Δ14MitP analogues described herein, minor changes to the privileged structure of MitP is a route
towards peptides with more desirable pharmacodynamic properties that are selective antibiotics. As an example of this strategy, the hydrophobic face of [Ser⁠14]MitP is disrupted by the
polar side chain of Ser indicated in red. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
chondrial outer membrane, the presumed initial site of accretion of
some but not all MitP analogues is a relatively simple phospholipid bi-
layer enriched in porin proteins. Conversely, the bacterial cell envelope
is a more variable and complex multi-layered structure [60]. The outer
membrane (OM), a distinguishing feature of Gram-negative bacteria, is
not a phospholipid bilayer but is predominantly composed of glycol-
ipids, principally the highly immunogenic lipopolysaccharide. A major-
ity of proteins located within the OM comprise either lipoproteins or
others of a ß-barrel tertiary structure including porins [60,61]. It is note-
worthy that, when screening a total of 15 antimicrobial peptides, melit-
tin, indolicidin and MP were identified as being effective against both
colistin-susceptible and colistin-resistant A. baumannii [8]. The potential
importance of the further development of Δ14MitP analogues to combat
A. baumannii infections, particularly in immunosuppressed patients, is
amplified by the identification of colistin-resistant A. baumannii clinical
isolates at the start of the new millennium [62]. Our data provide hope
that other Δ14MitP analogues might display enhanced activities against
A, baumannii and other pathogenic bacteria whilst maintaining the de-
sirable properties of [Ser⁠14]MitP in eukaryotic cell systems.
In common with the cell envelopes of bacteria, the composition of
fungal cell walls is also highly variable, structurally unique and pri-
marily composed of glycoproteins and polysaccharides [63]. There is
no double membrane system but, in order to access the plasma mem-
brane of fungi, antimicrobial peptides must cross a dynamic cell wall
that functions to maintain the structural integrity and metabolic func-
tion of the eukaryotic cell [63]. Indeed, there are major compositional
differences in the various layers of the cell wall of Candida and Cryp-
tococcus species, the latter being surrounded by a relatively thick poly-
saccharide capsule that can inhibit the function of phagocytes [64]. We
were, therefore, surprised to observe that a larger variety of screened
peptides, including all MitP analogues and an unrelated cationic se-
quences from LRRK2, were active against C. albicans and/or C. neofor-
mans. The Δ14MitP analogues are particularly promising and relatively
selective antifungal agents. These findings also suggest that cationic CPP
may induce fungal cell death by a common mode of action that is dis-
tinct from that of agents which target sterols or target cell wall synthe-
sis [65]. Since a majority of C. neoformans infections take place in the
lungs of immunocompromised patients [66], there is clearly scope to
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develop non-secretory analogues of MitP for topical application perhaps
combined with anti-HIV medications.
5. Conclusions
Collectively, our data indicate that MitP is a viable template for the
development of unique antibiotic peptides. It is now clear that rela-
tively minor changes to the core tetradecaptide sequence of either MP
or MitP can lead to distinct changes in activity. Furthermore, our studies
with Δ14MitP analogues have illustrated an effective route towards the
development of antimicrobials that lack detrimental activities against
eukaryotic cells. Molecular modelling, using computational algorithms
to define quantitative structure-activity relationships (QSAR) [67,68],
could be a useful strategy to further engineer MitP peptides. The oral
bioavailability of such peptides could be addressed by the incorpora-
tion of D-amino acids [56] or unnatural moieties [57] at labile sites
such as between position I⁠1 and N⁠2 [8]. Many other structural modifi-
cations to the privileged scaffold are also feasible [48], and more so-
phisticated strategies could be utilised to selectively deliver antibiotic
peptides to the sites of human infection [48]. Of particular relevance
to this study, a polymeric delivery system has been developed [69] to
direct MitP to human tumours. Self-assembled nanoparticles of cationic
antibiotic peptides, designed to disintegrate in contact with an anionic
bacterial cell surface, might also be adapted to deliver MitP analogues
in vivo [70]. Finally, Δ14MitP analogues could be combined with other
clinically useful antibiotics to improve efficacy and combat multiple-an-
tibiotic-resistant strains of bacteria and fungi [71].
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